CEL-SCI's CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
Posted on: Wednesday, 23 May 2007, 09:00 CDT
VIENNA, Va., May 23 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announces that CEL-1000 increased the immune response against H5 avian influenza antigen in combination with MAS-1, a water-in-oil adjuvant delivery system. These findings were presented on May 23, 2007 by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology at CEL-SCI at the American Society of Microbiologists 107th annual general meeting in Toronto, Canada.
This new finding with CEL-1000 may have broad application for the enhancement of immune responses by individuals who have a poor immune response to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen required for protective immunity), and to biodefense and pandemic settings for anti-infectious vaccines.
CEL-1000 has previously been shown to increase the antigenicity of hepatitis B virus (HBV). In challenge studies, CEL-1000 has also previously been shown to protect animals against infection against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria.
CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.
CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response. More information on CEL-1000 is available at http://www.cel-sci.com/.
MAS-1 is a water-in-oil adjuvant delivery system owned by Mercia Pharma.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter a global Phase III clinical trial for a first line indication in advanced primary head and neck cancer in the U.S. and Canada.
CEL-SCI Corporation
CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460
Web site: http://www.cel-sci.com/
Source: PRNewswire-FirstCall
Related Articles
- Northeast Utilities Releases First Corporate Social Responsibility Report
- UMC's 2008 Corporate Social Responsibility (CSR) Report Verified by DNV
- Lubrizol Names C. Lawrence Miller Corporate Vice President of Human Resources
- Pennsylvania Health Department Reminds Parents to Immunize Their Children Against Pertussis
- First US Corporate Social Responsibility Report Published By National Grid
- HomePlug(R) Powerline Alliance Welcomes New Contributor Members Huawei Technologies and Corporate Systems Engineering
- TECO Energy Publishes Corporate Social Responsibility Report
- New Research Available Tracking Public Opinion in Brazil on the Role of Companies and the Influence of Corporate Social Responsibility Issues Among Consumers
- Surgical Endoscopy Publishes Data Evaluating Dosing and Ablation Depth of the HALO360 System in the Human Esophagus: A Technology Relevant As a Current Treatment for Barrett's Esophagus
- Corporate Social Responsibility: Hard Choices on Soft Issues
 |
 |
User Comments (0)
RSS Feeds